Intuit On Track for Highest Close Since February 2022 — Data Talk
Intuit Inc. (INTU) is currently at $515.38, up $16.88 or 3.39%
--Would be highest close since Feb. 16, 2022, when it closed at $528.15
--On pace for largest percent increase since July 10, 2023, when it rose 3.6%
--Currently up three of the past five days
--Up 0.72% month-to-date
--Up 32.41% year-to-date
--Down 25.81% from its all-time closing high of $694.66 on Nov. 29, 2021
--Up 14.92% from 52 weeks ago (Aug. 26, 2022), when it closed at $448.46
--Would be a new 52-week closing high
--Up 42.69% from its 52-week closing low of $361.19 on Nov. 4, 2022
--Traded as high as $517.15; highest intraday level since Feb. 17, 2022, when it hit $525.90
--Up 3.74% at today's intraday high; largest intraday percent increase since July 10, 2023, when it rose as much as 4.11%
--Second best performer in the S&P 500 today
--Second best performer in the Nasdaq 100 today
All data as of 1:25:47 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
August 25, 2023 13:43 ET (17:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track